Recombinant thrombopoietin and thrombopoietin receptor agonists have been explored as therapeutic agents to mitigate thrombocytopenia in cancer patients. These agents aim to stimulate platelet production and reduce the need for platelet transfusions, improving the patient's quality of life and allowing for uninterrupted cancer treatment.
